Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pralidoxime continuous infusion versus intermittent bolus for organophosphate poisoning
IRCT20180613040087N1Phase 3Completed
- Sponsor
- Shiraz University of Medical Sciences
- Start
- Jul 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of pralidoxime in organophosphate poisoning (2 arms), sponsored by Shiraz University of Medical Sciences. Primary endpoints: Duration of atropine therapy and Duration of ICU stay. Started Jul 2018; status: completed.
02
Drugs
pralidoxime
03
Conditions
organophosphate poisoning
Beyond the preview
Go deeper on IRCT20180613040087N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20180613040087N1.